Skip to main content
. 2023 Jul 29;12(8):1525. doi: 10.3390/antiox12081525

Figure 4.

Figure 4

Cartoon summarizing the data on redox stress and YPs interplay in the context of the neurologic conditions. TSB: total serum bilirubin; UCB: unconjugated bilirubin; BVLRA: biliverdin reductase A; DOPAn: dopaminergic neurons; HMOX1: heme oxygenase 1; SOD: superoxide dismutase; TDP43: TAR DNA-binding protein 43; ANG: angiogenin; FUS: FUS RNA binding protein; C9orf72: chromosome 9 open reading frame 72 protein; NRF2: NFE2L2 NFE2 like bZIP transcription factor 2; ARE: antioxidant responsive elements; NFEL2: the gene encoding for the nuclear factor, erythroid 2; PPARs: peroxisome proliferator-activated receptor; AGE: advanced glycation end products; RAGE: receptor for advanced glycation end products; YPs: yellow players; ROS: reactive oxygen species; GSH: reduced glutathione; NCDs: neurologic and neurodegenerative diseases; NMDA: N-methyl-D-aspartate receptor; AHR: aryl hydrocarbon receptor; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; LDL: low density lipoprotein; Gpx: glutathione peroxidase; GRM1: metabotropic glutamate receptor 1; CACNG8: calcium voltage-gated channel auxiliary subunit gamma 8; CACNA2D4: alpha-2/delta voltage-dependent calcium channel; CAMLG: calcium modulating ligand; SLC39A12: solute carrier 39 member 12; TNR: tenascin receptor. References used: Oxidative stress/YP’s interplay. MS, multiple sclerosis: 52, 93–96/97–101. AD, Alzheimer disease: 63–67/60, 68–70, 72, 73. HD, Huntington’s disease: 126–128, 133, 134/12, 135–137, PD, Parkinson’s disease: 76–80/3, 80–83, 85, 86. ALS, amyotrophic lateral sclerosis: 105–107, 110–115, 117–119/120–123. TS, telomere stability: 216, 217/218–220. VaD, vascular dementia: 149–151, 155/9, 136, 152, 153, 156–158. DLB, dementia with Lewy bodies: 139–143/144, 145. A-MSA, ataxia and multiple system atrophy: 201/32, 37, 202. SCZ: schizophrenia: 164–172/173–177, 185–190. BT, brain tumors: 207–209, 212, 213/210, 211, 214, 215.